6-K
Renalytix plc (RNLXY)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OFFOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date of report: December 7, 2020
Commission File Number: 001-39387
Renalytix AI plc
(Translation of registrant’s name into English)
Avon House
19 Stanwell Road
Penarth
Cardiff CF64 2EZ
United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On December 7, 2020, Renalytix AI plc issued a press release announcing the results of its Annual General Meeting, which is furnished as Exhibit 99.1 to this Report on Form 6-K.
EXHIBIT INDEX
| Exhibit | Description |
|---|---|
| 99.1 | Press release dated December 7, 2020. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| RENALYTIX AI PLC | |
|---|---|
| By: | /s/ James McCullough |
| James McCullough | |
| Chief Executive Officer |
Date: December 7, 2020
EX-99.1
Exhibit 99.1
Renalytix AI plc
(“RenalytixAI” or the “Company”)
Result of AGM
Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that at the Annual General Meeting (“AGM”) held earlier today, all resolutions were duly passed.
The results of the AGM are detailed below:
| Votes in Favour<br>(% of votes cast) | Votes against<br>(% of votes cast) | Votes withheld | ||||||
|---|---|---|---|---|---|---|---|---|
| Resolution 1 | 42,245,505 (91.38% | ) | 3,986,275 (8.62% | ) | 2,569 | |||
| Resolution 2 | 41,548,352 (89.87% | ) | 4,685,392 (10.13% | ) | 605 | |||
| Resolution 3 | 46,228,154 (99.99% | ) | 1,526 (0.01% | ) | 4,669 | |||
| Resolution 4 | 46,190,220 (99.91% | ) | 43,624 (0.09% | ) | 505 | |||
| Resolution 5 | 46,071,032 (99.66% | ) | 157,813 (0.34% | ) | 5,504 | |||
| Resolution 6 | 46,095,710 (99.73% | ) | 127,083 (0.27% | ) | 11,556 | |||
| Resolution 7 | 45,551,130 (99.88% | ) | 54,530 (0.12% | ) | 628,689 |
Enquiries:
| Renalytix AI plc | www.renalytixai.com |
|---|---|
| James McCullough, CEO | Via Walbrook PR |
| Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 |
| Alex Price / Nicholas Moore | |
| Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 |
| Gary Clarence / Daniel Adams | |
| Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com |
| Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / 07584 391 303 |
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a “silent killer” because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.
* https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI’s products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com.